Aside from a failure on management of benefits, the complaint alleges multiple violations of ERISA, all stemming from Anthems failure to document and disclose the basis for its denial: The Compliance Breakdown: A Lack of Necessary Documentation This case is not about a dispute over medical necessity or clinical judgment
Stanford Medicine Insights: Stanford Report (alternate): 3

Sermorelin and Bupropion Interaction: Safety, Mechanisms, and Clinical Guidance At a glance Interaction severity / low (no shared metabolic pathway) Sermorelin clearance / peptidase-mediated, not CYP-dependent Bupropion metabolism / primarily CYP2B6, with CYP2D6 inhibition Seizure risk with bupropion / dose-dependent, 0.4% at 450 mg/day IGF-1 monitoring interval / every 4 to 6 weeks after initiation Fasting glucose check / recommended within 30 days of co-prescribing GH peak after sermorelin / 60 to 90 minutes post-injection Bupropion half-life / 21 hours (hydroxybupropion active metabolite) FDA sermorelin status / previously approved, now available via 503A compounding Evidence level for this combination / no published case reports of adverse interaction Why This Drug Pair Gets Flagged Patients prescribed sermorelin for growth hormone optimization and bupropion for depression or smoking cessation frequently ask whether the two medications conflict

Severe stomach pain, abdominal swelling, loss of appetite, inability to pass gas, rectal bleeding, or vomiting warrant contacting a healthcare provider